研究文章
在波兰的系统性红斑狼疮患者血清Interleukin-23:协会与狼疮肾炎、肥胖和周围性血管疾病
表5
血清学特征的系统性红斑狼疮患者和健康对照组。
|
| 自身抗体 |
系统性红斑狼疮患者
(%) |
健康对照组
(%) |
|
| 抗核抗体免疫球蛋白 |
73例(77.7%) |
2 (7.4%) |
| Anti-double链DNA免疫球蛋白 |
37 (39.4%) |
0 (0.0%) |
| Anti-nucleosome免疫球蛋白 |
30 (31.9%) |
0 (0.0%) |
| Anti-Sm免疫球蛋白 |
4 (4.3%) |
0 (0.0%) |
| Anti-SS-A / Ro免疫球蛋白 |
42 (44.7%) |
0 (0.0%) |
| Anti-SS-B / La免疫球蛋白 |
14 (14.9%) |
0 (0.0%) |
| Anti-ribosomal P蛋白免疫球蛋白 |
6 (6.4%) |
0 (0.0%) |
| Anti-histone免疫球蛋白 |
19 (20.2%) |
0 (0.0%) |
| Anti-U1-RNP免疫球蛋白 |
20 (21.3%) |
0 (0.0%) |
| Anti-cardiolipin免疫球蛋白 |
33 (35.1%) |
0 (0.0%) |
| Anti-cardiolipin IgM |
19 (20.2%) |
1 (3.7%) |
| Anti-cardiolipin IgA |
40 (42.6%) |
1 (3.7%) |
| Anti-beta2-glycoprotein我免疫球蛋白 |
7 (7.4%) |
0 (0.0%) |
| Anti-beta2-glycoprotein我IgM |
23 (24.5%) |
1 (3.7%) |
| Anti-beta2-glycoprotein我IgA |
23 (24.5%) |
0 (0.0%) |
| Anti-oxidized低密度脂蛋白免疫球蛋白 |
45 (47.9%) |
0 (0.0%) |
| Anti-oxidized低密度脂蛋白IgM |
68例(72.3%) |
0 (0.0%) |
| Anti-prothrombin免疫球蛋白 |
10 (10.6%) |
0 (0.0%) |
| Anti-prothrombin IgM |
12 (12.8%) |
0 (0.0%) |
| Anti-prothrombin IgA |
11 (11.7%) |
0 (0.0%) |
| Anti-phosphatidylserine免疫球蛋白 |
7 (7.4%) |
0 (0.0%) |
| Anti-phosphatidylserine IgM |
6 (6.4%) |
1 (3.7%) |
| Anti-phosphatidylethanolamine免疫球蛋白 |
12 (12.8%) |
0 (0.0%) |
| Anti-phosphatidylethanolamine IgM |
6 (6%) |
0 (0.0%) |
| 狼疮抗凝剂 |
15 (16.0%) |
0 (0.0%) |
| Anti-neutrophil胞质抗体免疫球蛋白 |
39 (41.5%) |
2 (7.4%) |
| Anti-proteinase 3免疫球蛋白 |
0 (0.0%) |
0 (0.0%) |
| Anti-myeloperoxidase免疫球蛋白 |
9 (9.6%) |
0 (0.0%) |
| Anti-lactoferrin免疫球蛋白 |
12 (12.8%) |
0 (0.0%) |
| Anti-elastase免疫球蛋白 |
9 (9.6%) |
0 (0.0%) |
| Anti-BPI免疫球蛋白 |
1 (1.1%) |
0 (0.0%) |
| Anti-endothelial细胞抗体免疫球蛋白 |
42 (44.7%) |
3 (11.1%) |
|
|
BPI:杀菌/ permeability-increasing蛋白质。
|
